ATE343591T1 - Antagonist für die multimerisierung von hiv-1 vif-protein - Google Patents

Antagonist für die multimerisierung von hiv-1 vif-protein

Info

Publication number
ATE343591T1
ATE343591T1 AT02764001T AT02764001T ATE343591T1 AT E343591 T1 ATE343591 T1 AT E343591T1 AT 02764001 T AT02764001 T AT 02764001T AT 02764001 T AT02764001 T AT 02764001T AT E343591 T1 ATE343591 T1 AT E343591T1
Authority
AT
Austria
Prior art keywords
vif
multimerization
hiv
antagonist
multimerization domain
Prior art date
Application number
AT02764001T
Other languages
English (en)
Inventor
Hui Zhang
Roger Pomerantz
Bin Yang
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of ATE343591T1 publication Critical patent/ATE343591T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02764001T 2001-04-06 2002-04-08 Antagonist für die multimerisierung von hiv-1 vif-protein ATE343591T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28227001P 2001-04-06 2001-04-06

Publications (1)

Publication Number Publication Date
ATE343591T1 true ATE343591T1 (de) 2006-11-15

Family

ID=23080751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02764001T ATE343591T1 (de) 2001-04-06 2002-04-08 Antagonist für die multimerisierung von hiv-1 vif-protein

Country Status (8)

Country Link
US (4) US6653443B2 (de)
EP (1) EP1373308B1 (de)
JP (1) JP4234999B2 (de)
AT (1) ATE343591T1 (de)
AU (1) AU2002307229B2 (de)
CA (1) CA2442909C (de)
DE (1) DE60215626T2 (de)
WO (1) WO2002081504A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7138496B2 (en) * 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
CA2439472A1 (en) * 2001-02-27 2002-09-06 University Of Rochester Methods and compositions for modifying apolipoprotein b mrna editing
AU2002307229B2 (en) 2001-04-06 2007-05-24 Thomas Jefferson University Multimerization of HIV-1 Vif protein as a therapeutic target
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US7635681B2 (en) 2002-01-09 2009-12-22 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20050123973A1 (en) * 2002-02-08 2005-06-09 Shaobing Hua Methods for generating monoclonal antibody against fusion protein containing peptide fragment derived from membrane protein
US20050287648A1 (en) * 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
DE602004012406T2 (de) * 2003-05-23 2009-04-30 Oregon Health & Science University, Portland Verfahren zur identifikation von inhibitoren
US20050014137A1 (en) * 2003-07-17 2005-01-20 Agouron Pharmaceuticals, Inc. Lentivirus assay system including Vif protein activity
CA2537798A1 (en) * 2003-09-03 2005-03-17 University Of Rochester Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
EP1687022A4 (de) * 2003-11-12 2008-02-13 Medical Res Council Renta: hiv-immunogen und seine anwendungen
WO2005115410A2 (en) * 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
CA2596448A1 (en) 2005-02-11 2006-08-11 University Of Rochester Methods and compositions related to heightened apobec-1 related protein (arp) expression
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8334255B2 (en) 2006-12-06 2012-12-18 Thomas Jefferson University Peptide and treatment for HIV-1 infection
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US20150272959A1 (en) * 2012-10-04 2015-10-01 Oyagen, Inc. Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof
US10588902B2 (en) 2013-06-24 2020-03-17 Oyagen, Inc. Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US11116762B2 (en) 2017-01-04 2021-09-14 Oyagen, Inc. Compounds, compositions, and methods for treating human immunodeficiency virus
EP3678699A1 (de) 2017-09-07 2020-07-15 University Of Oslo Impfstoffmoleküle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (de) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Zusammensetzung, verwendbar zur Diagnose und Behandlung von HIV-I-Infektion
AU7568794A (en) 1993-08-20 1995-03-21 St. Luke's-Roosevelt Hospital Center Hiv (vif)-related compositions, and prophylactic and therapeutic uses thereof
WO1998052970A1 (en) 1997-05-20 1998-11-26 St. Luke's-Roosevelt Hospital Vif-derived hiv protease inhibitors
EP0959136A1 (de) * 1998-05-20 1999-11-24 Introgene B.V. Bei einem transporter von kationischen Aminosaüren zielgerichtete Darreichung
AU2002307229B2 (en) 2001-04-06 2007-05-24 Thomas Jefferson University Multimerization of HIV-1 Vif protein as a therapeutic target

Also Published As

Publication number Publication date
CA2442909C (en) 2011-11-29
AU2002307229B2 (en) 2007-05-24
JP2005516885A (ja) 2005-06-09
US6653443B2 (en) 2003-11-25
US20030013844A1 (en) 2003-01-16
US7226741B2 (en) 2007-06-05
US20040086512A1 (en) 2004-05-06
DE60215626D1 (de) 2006-12-07
WO2002081504A2 (en) 2002-10-17
US20040146522A1 (en) 2004-07-29
EP1373308B1 (de) 2006-10-25
DE60215626T2 (de) 2007-08-30
EP1373308A2 (de) 2004-01-02
US20080167199A1 (en) 2008-07-10
US7498138B2 (en) 2009-03-03
WO2002081504A3 (en) 2003-04-10
JP4234999B2 (ja) 2009-03-04
CA2442909A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
DE60215626D1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
ES2505144T3 (es) Agentes de unión selectivos antagonistas de proteína de unión de osteoprotegerina
ATE540319T1 (de) Verfahren für die bestimmung von fk506
ATE544870T1 (de) Profilierung einer rezeptorfamilie
WO2007035633A3 (en) Screening assays and methods
EA200901646A1 (ru) Ингибиторы рецепторных тирозинкиназ и их применение
UA108860C2 (xx) Моноклональне антитіло
CY1108580T1 (el) Αυτοανοσες παθησεις και ελλειμματα nadph οξειδασης
ATE454404T1 (de) Intrazelluläre antikörper
ATE388961T1 (de) Verfahren zur identifikation von inhibitoren
ATE524561T1 (de) Verfahren zur bestimmung einer allergenreaktion unter verwendung von mikroarray-immunoassay- techniken
DE602004015791D1 (de) Screening-Verfahren zur Identifizierung von Tau-Protein modulierenden Substanzen.
DE602004017884D1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
DK1864131T3 (da) Naturlig ligand af G protein koblet receptor RCC356 og anvendelser deraf
WO2005114219A3 (en) Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
TW200700089A (en) Recombinant protein comprising starch binding domain and use thereof
ATE466884T1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
DE60138130D1 (de) Proteomanalyse verfahren zum drogen vergleich
DE60331059D1 (de) Verbesserter rezeptornachweis
ATE331038T1 (de) Verbessertes verfahren für reverses n-hybrid- screening
ATE368750T1 (de) Screening-verfahren zum identifizieren von g- proteinen und anderen verbindungen,die die phosphodiesterase (pde)-aktivität beeinflussen
ATE447610T1 (de) Kristalliner vap-1 und verwendung
ATE412187T1 (de) Screening test
NO20035771L (no) Assays for EPF-reseptorforbindelser samt terapeutiske sammensetninger
DK1294924T3 (da) Kompetitivt assay til identificering af allosteriske inhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties